Amygdala is a biopharmaceutical company focused on improving public health by developing and commercializing first-in-class therapy to treat substance use disorders. Early stage development programs include treatment and prevention of opioid, nicotine, alcohol and cocaine use disorders. Amygdala was founded and is led by industry leaders and therapeutic experts who include: Executive Chairman Lou Lange, MD, PhD; Chief Scientific Officer Ivan Diamond, MD, PhD; President and Chief Executive Officer Peter Strumph; Chief Development Officer Brent Blackburn, PhD; and Chief Financial Officer Adrienne MacMillan.